Interviews

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, provides an overview of the evolving treatment landscape in Fabry disease.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.

Next Gen ACO recently re-branded as the Value Based Care Coalition. To learn more about the organization's new phase, we spoke with executive director Mara McDermott.

John Burke, MD, hematologist, Rocky Mountain Cancer Centers, discussed findings of the late-breaking abstract session POLARIX presented at ASH 2021, which compared pola-R-CHP with standard-of-care R-CHOP in patients with previously untreated DLBCL.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, outlines potential mechanisms underlying menstrual-related migraine.

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.

Sattva S. Neelapu, MD, professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses findings of the ZUMA-12 study examining axicabtagene ciloleucel (axi-cel) as a first-line treatment option for high-risk patients with large B-cell lymphoma.

Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center, explains certain considerations ophthalmologists may need to take into account when treating older patients and the need for more specialists to meet clinical demand.

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Lori Muffly, MD, associate professor of medicine, Blood & Marrow Transplantation, Stanford University, discusses findings of her study showing disparities in clinical trial enrollment and patient outcomes for at-risk pediatric minority populations with acute lymphoblastic leukemia (ALL).

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, speaks on molecular features of diffuse large B-cell lymphoma and how this explains differences in patient response for chemotherapy and chimeric antigen receptor (CAR) T-cell therapy.

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, discusses the superior safety and progression-free survival outcomes from the SEQUOIA phase 3 trial, which compared zanubrutinib with bendamustine and rituximab combination therapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma.

Chronic cough can be very debilitating to a patient's quality of life, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

L. Elizabeth Budde, MD, PhD, oncologist and associate professor at City of Hope, discusses the use of mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL) who have received 2 or more prior lines of therapy and addresses potential cost-related implications of the drug compared with CAR T-cell therapy.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, speaks on common misconceptions when designing value-based benefits.

Theresa Juday, RPh, director, Specialty Product Development, CVS Health, discusses the indirect and direct cost burden associated with chronic insomnia.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, speaks on misconceptions regarding Fabry disease and opportunities for improvement in care.

On this episode of Managed Care Cast, guests discuss why pharmacists are in a unique position to help address social determinants of health (SDOH) and the importance of incorporating patients’ perspectives into research agendas.

Aaron Lee, MD, an associate professor of ophthalmology at the University of Washington, explains why raising the standard of medical knowledge of artificial intelligence (AI) in ophthalmology is important.

Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine and director of the Montefiore Cough Center, discusses what he and others have seen during the pandemic in patients with chronic cough who had COVID-19.

Misinformation about flu vaccines must be dealt with immediately, according to Leslie Kantor, PhD, MPH, chair and professor of the Department of Urban-Global Public Health, Rutgers School of Public Health.

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine, speaks on the common occurrence of other comorbidities in patients with chronic insomnia.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, addresses major unmet needs in Fabry disease, ranging from uncontrolled pain to irreversible damage prior to treatment initiation.

Victoria Ly, MD, MPH, outlines one method of tackling vision screening follow-up rate disparities among children in Arkansas.

Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses the shift to a value-based system from a fee-for-service one and how the health care system can incentivize high-value care.

Judith Lavrich, MD, and Jordan Hamburger discuss what additional studies need to be carried out in order to better understand the effects of virtual learning on children's long-term eye health.

Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. Here, he explains how sodium-glucose co-transporter 2 (SGLT2) inhibitors can treat metabolic physiologic effects of sleep apnea.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, details various known and understudied health-related quality-of-life factors in patients with Fabry disease.

It’s right to acknowledge that dental, hearing, and vision are important for total health care for Medicare beneficiaries, said Melissa Andel, MPP, vice president of health policy at CommonHealth Solutions.